According to the Article 66 par. 7a of Law 4316/2014, pharmaceutical companies in Greece are required to disclose every benefit they provide to Health Care Professionals (HCPs) and Scientific Health Care Providers (SHPs).

Benefits related to Research and Development activities and non-interventional studies (with or without a drug) will be disclosed in aggregate by each pharmaceutical company.

Explicitly excluded from the disclosure obligation are the costs of market research, meals and drinks, as well as items of negligible value of medical and educational applications, which are directly related to the conduct of the daily medical practice of Health Professionals and Scientific Healthcare Providers, according to the Article 126 par. 1 the ministerial decision DYΓ3a /ΓΠ 3221/2013 (B’ 1049).

Negligible value means any item whose value does not exceed the total amount of fifteen (15) euros including VAT.

Publication Methodology 2021
Publication of Data 2021
Publication Methodology 2022
Publication of Data 2022